|
GEP20217326B
(en)
|
2015-08-07 |
2021-11-25 |
Alx Oncology Inc |
Constructs having a sirp-alpha domain or variant thereof
|
|
RS66062B1
(sr)
|
2016-04-14 |
2024-11-29 |
Ose Immunotherapeutics |
Nova anti-sirpa antitela i njihove terapijske primene
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
KR20240039236A
(ko)
|
2016-12-09 |
2024-03-26 |
알렉터 엘엘씨 |
항-sirp-알파 항체 및 그의 사용 방법
|
|
WO2018149938A1
(en)
*
|
2017-02-17 |
2018-08-23 |
Ose Immunotherapeutics |
New uses of anti-sirpg antibodies
|
|
SG11201908813QA
(en)
|
2017-04-13 |
2019-10-30 |
Aduro Biotech Holdings Europe B V |
Anti-sirp alpha antibodies
|
|
US11203611B2
(en)
|
2017-04-14 |
2021-12-21 |
Tollnine, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
|
MX2019013749A
(es)
|
2017-05-16 |
2020-01-15 |
Synthon Biopharmaceuticals Bv |
Anticuerpos anti-sirpalfa.
|
|
NZ761568A
(en)
|
2017-08-02 |
2022-11-25 |
Phanes Therapeutics Inc |
Anti-cd47 antibodies and uses thereof
|
|
EP3694881A1
(en)
|
2017-10-13 |
2020-08-19 |
OSE Immunotherapeutics |
Modified anti-sirpa antibodies and uses thereof
|
|
CN111278865B
(zh)
*
|
2017-10-26 |
2023-04-25 |
盛禾(中国)生物制药有限公司 |
新的重组融合蛋白及其制备和用途
|
|
KR20210006338A
(ko)
*
|
2018-03-13 |
2021-01-18 |
오제 이뮈노테라프틱스 |
항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법
|
|
WO2019178218A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Memorial Sloan Kettering Cancer Center |
Anti-polysialic acid antibodies and uses thereof
|
|
EP4144372A3
(en)
|
2018-03-21 |
2023-06-14 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein alpha and methods of use
|
|
MX2020011828A
(es)
|
2018-05-25 |
2021-02-09 |
Alector Llc |
Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
|
|
IL317587A
(en)
|
2018-07-10 |
2025-02-01 |
Univ Kobe Nat Univ Corp |
Antibody against SIRPalpha
|
|
US20230242640A1
(en)
*
|
2018-08-22 |
2023-08-03 |
Ose Immunotherapeutics |
ANTI-SIRPg Compounds
|
|
AU2019349651B2
(en)
*
|
2018-09-27 |
2023-12-07 |
Celgene Corporation |
SIRP alpha binding proteins and methods of use thereof
|
|
US11591390B2
(en)
|
2018-09-27 |
2023-02-28 |
Celgene Corporation |
SIRP-α binding proteins and methods of use thereof
|
|
EP3873522A1
(en)
|
2018-10-29 |
2021-09-08 |
UMC Utrecht Holding B.V. |
Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
|
|
CN113573728A
(zh)
*
|
2018-11-14 |
2021-10-29 |
安驰肿瘤公司 |
治疗性SIRPα抗体
|
|
US12180295B2
(en)
*
|
2018-11-15 |
2024-12-31 |
Byondis B.V. |
Humanized anti-SIRPα antibodies
|
|
JP7675012B2
(ja)
*
|
2018-12-21 |
2025-05-12 |
オーエスイー・イミュノセラピューティクス |
二機能性抗ｐｄ－１／ｓｉｒｐａ分子
|
|
US20220143210A1
(en)
*
|
2019-02-27 |
2022-05-12 |
Fred Hutchinson Cancer Research Center |
Hydrogel compositions and methods for treatement of malignancies
|
|
WO2020180811A1
(en)
*
|
2019-03-04 |
2020-09-10 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-sirp-alpha antibodies
|
|
AU2020282791A1
(en)
|
2019-05-31 |
2021-12-09 |
ALX Oncology Inc. |
Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
|
|
EP3980747A1
(en)
|
2019-06-07 |
2022-04-13 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
EP3756688A1
(en)
|
2019-06-25 |
2020-12-30 |
Université de Nantes |
Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
CN112867507B
(zh)
*
|
2019-08-20 |
2025-03-04 |
科望(苏州)生物医药科技有限公司 |
新型抗sirpa抗体
|
|
CN118178645A
(zh)
|
2019-10-18 |
2024-06-14 |
四十七公司 |
用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
|
|
KR20220091576A
(ko)
|
2019-10-31 |
2022-06-30 |
포티 세븐, 인코포레이티드 |
혈액암의 항-cd47 및 항-cd20 기반 치료
|
|
BR112022008817A2
(pt)
|
2019-11-27 |
2022-07-26 |
Alx Oncology Inc |
Terapias combinadas para tratamento de câncer
|
|
HRP20241518T1
(hr)
|
2019-12-24 |
2025-01-03 |
Carna Biosciences, Inc. |
Spojevi koji moduliraju diacilglicerinkinazu
|
|
CN111116713B
(zh)
*
|
2020-01-07 |
2023-06-23 |
郑州大学 |
Sirpa蛋白亲和环肽及其应用
|
|
PH12022552122A1
(en)
|
2020-02-14 |
2024-01-29 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
|
KR20220162130A
(ko)
|
2020-02-28 |
2022-12-07 |
탈락 테라퓨틱스, 인크. |
트랜스글루타미나제-매개된 접합
|
|
KR20230012559A
(ko)
|
2020-05-19 |
2023-01-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료를 위한 결합 분자
|
|
JP2023528341A
(ja)
|
2020-06-01 |
2023-07-04 |
エーエルエックス オンコロジー インコーポレイテッド |
低メチル化剤を含むがんを治療するための併用療法
|
|
IL302812A
(en)
|
2020-11-11 |
2023-07-01 |
Daiichi Sankyo Co Ltd |
Antibody-drug conjugate combinations with anti-SIRP alpha antibody
|
|
WO2022110922A1
(zh)
|
2020-11-30 |
2022-06-02 |
启愈生物技术(上海)有限公司 |
抗SIRPα抗体或其抗原结合片段及应用
|
|
JP2023552375A
(ja)
|
2020-12-06 |
2023-12-15 |
エーエルエックス オンコロジー インコーポレイテッド |
血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CA3216908A1
(en)
|
2021-05-13 |
2022-11-17 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
CN117355539A
(zh)
*
|
2021-05-28 |
2024-01-05 |
百奥泰生物制药股份有限公司 |
抗SIRPα抗体及其应用
|
|
US11572412B2
(en)
|
2021-06-04 |
2023-02-07 |
Boehringer Ingelheim International Gmbh |
Anti-SIRP-alpha antibodies
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11976072B2
(en)
|
2021-06-23 |
2024-05-07 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
EP4362977A1
(en)
|
2021-06-29 |
2024-05-08 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
|
EP4389767A1
(en)
|
2021-08-17 |
2024-06-26 |
Hangzhou Jiuyuan Gene Engineering Co., Ltd |
Monoclonal antibody targeting sirp? and use thereof
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
CR20240173A
(es)
|
2021-10-29 |
2024-06-20 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
CN118679183A
(zh)
|
2021-11-29 |
2024-09-20 |
Ose免疫疗法公司 |
特异性拮抗剂抗sirpg抗体
|
|
JP2024546851A
(ja)
|
2021-12-22 |
2024-12-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
JP2025509610A
(ja)
|
2022-03-17 |
2025-04-11 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
WO2023183817A1
(en)
|
2022-03-24 |
2023-09-28 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
JP2025513258A
(ja)
|
2022-04-21 |
2025-04-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａ ｇ１２ｄ調節化合物
|
|
JPWO2023219072A1
(pt)
|
2022-05-10 |
2023-11-16 |
|
|
|
WO2023235754A1
(en)
|
2022-06-01 |
2023-12-07 |
ALX Oncology Inc. |
Combination therapies for treating urothelial carcinoma
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024105180A1
(en)
|
2022-11-16 |
2024-05-23 |
Boehringer Ingelheim International Gmbh |
Predictive efficacy biomarkers for anti-sirpa antibodies
|
|
KR20250122479A
(ko)
|
2022-12-22 |
2025-08-13 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
EP4687991A1
(en)
|
2023-03-30 |
2026-02-11 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
WO2024200826A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025024663A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN119192379B
(zh)
*
|
2024-11-22 |
2025-01-28 |
四川省医学科学院·四川省人民医院 |
一种具有高亲和力的抗SIRPγ单克隆抗体及其用途
|